Evidence map›Paper›PMID 34475445›Full record

ArticleScientific reports2021

Screening and predicting progression from high-risk mild cognitive impairment to Alzheimer's disease.

Xiao-Yan Ge, Kai Cui, Long Liu, Yao Qin, Jing Cui, Hong-Juan Han, Yan-Hong Luo, Hong-Mei Yu

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiao-Yan GeDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China.
Kai CuiDepartment of Health Statistics, School of Public Health, Jinzhou Medical University, 40 SongPo Road, Jinzhou, China.
Long LiuDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China.
Yao QinDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China.
Jing CuiDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China.
Hong-Juan HanDepartment of Mathematics, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China.
Yan-Hong LuoDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China.
Hong-Mei YuDepartment of Health Statistics, School of Public Health, Shanxi Medical University, 56 XinJian South Road, Taiyuan, China. yu@sxmu.edu.cn.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Individuals with mild cognitive impairment (MCI) are clinically heterogeneous, with different risks of progression to Alzheimer's disease. Regular follow-up and examination may be time-consuming and costly, especially for MRI and PET. Therefore, it is necessary to identify a more precise MRI population. In this study, a two-stage screening frame was proposed for evaluating the predictive utility of additional MRI measurements among high-risk MCI subjects. In the first stage, the K-means cluster was performed for trajectory-template based on two clinical assessments. In the second stage, high-risk individuals were filtered out and imputed into prognosis models with varying strategies. As a result, the ADAS-13 was more sensitive for filtering out high-risk individuals among patients with MCI. The optimal model included a change rate of clinical assessments and three neuroimaging measurements and was significantly associated with a net reclassification improvement (NRI) of 0.246 (95% CI 0.021, 0.848) and integrated discrimination improvement (IDI) of 0.090 (95% CI - 0.062, 0.170). The ADAS-13 longitudinal models had the best discrimination performance (Optimism-corrected concordance index = 0.830), as validated by the bootstrap method. Considering the limited medical and financial resources, our findings recommend follow-up MRI examination 1 year after identification for high-risk individuals, while regular clinical assessments for low-risk individuals.

Indexed as

AgedAlzheimer DiseaseCognitive DysfunctionDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleNeuroimagingNeuropsychological TestsPositron-Emission TomographyPrognosisRisk FactorsROC CurveSurvival Rate

Identifiers

PMID34475445
PMCPMC8413294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.